Research progress of FAPI PET/CT in the diagnosis of malignant liver tumors / 中华肝脏病杂志
Chinese Journal of Hepatology
; (12): 664-667, 2023.
Article
in Zh
| WPRIM
| ID: wpr-986189
Responsible library:
WPRO
ABSTRACT
Malignant liver tumors have a high incidence and mortality rate. Therefore, it is of great significance to promptly learn about tumor advancement status through relevant examinations for patients' follow-up, diagnosis, and therapy as well as the improvement of the five-year survival rate. The primary lesions and intrahepatic metastases of malignant liver tumors have been better demonstrated in the clinical study with the use of various isotope-labeled fibroblast activating protein inhibitors because of their low uptake in liver tissues and high tumor/background ratio, which provides a new method for early diagnosis, precise staging, and radionuclide therapy. In light of this context, a review of the research progress of fibroblast-activating protein inhibitors for the diagnosis of liver malignant tumors is presented.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Carcinoma, Hepatocellular
/
Positron Emission Tomography Computed Tomography
/
Liver Neoplasms
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Hepatology
Year:
2023
Type:
Article